Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock par value $0.012 per share
-
Shares outstanding
-
41,009,592
-
Total 13F shares
-
4,261,808
-
Share change
-
+705,515
-
Total reported value
-
$9,288,923
-
Put/Call ratio
-
65%
-
Price per share
-
$2.18
-
Number of holders
-
58
-
Value change
-
-$8,243,251
-
Number of buys
-
24
-
Number of sells
-
45
Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) as of Q1 2023
As of 31 Mar 2023,
ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,261,808 shares.
The largest 10 holders included
BML Capital Management, LLC, TWO SIGMA INVESTMENTS, LP, TWO SIGMA ADVISERS, LP, MORGAN STANLEY, JPMORGAN CHASE & CO, MILLENNIUM MANAGEMENT LLC, XTX Topco Ltd, Susquehanna International Group Ltd., GOLDMAN SACHS GROUP INC, and UBS Group AG.
This page lists
58
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.